KR100791872B1 - 신규 서트랄린 염산염 다형, 그것의 제조 방법, 그것을 함유하는 조성물, 및 그것을 사용하는 방법 - Google Patents
신규 서트랄린 염산염 다형, 그것의 제조 방법, 그것을 함유하는 조성물, 및 그것을 사용하는 방법 Download PDFInfo
- Publication number
- KR100791872B1 KR100791872B1 KR1020027007897A KR20027007897A KR100791872B1 KR 100791872 B1 KR100791872 B1 KR 100791872B1 KR 1020027007897 A KR1020027007897 A KR 1020027007897A KR 20027007897 A KR20027007897 A KR 20027007897A KR 100791872 B1 KR100791872 B1 KR 100791872B1
- Authority
- KR
- South Korea
- Prior art keywords
- sertraline hydrochloride
- hydrochloride
- sertraline
- solvent
- suspension
- Prior art date
Links
- GLQPTZAAUROJMO-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)benzaldehyde Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=C(C=O)C=C1 GLQPTZAAUROJMO-UHFFFAOYSA-N 0.000 title claims abstract description 483
- 229960003660 sertraline hydrochloride Drugs 0.000 title claims abstract description 476
- 238000000034 method Methods 0.000 title claims description 108
- 239000000203 mixture Substances 0.000 title claims description 62
- 238000004519 manufacturing process Methods 0.000 claims abstract description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 87
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 86
- 239000000725 suspension Substances 0.000 claims description 86
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 69
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 66
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 66
- 239000002904 solvent Substances 0.000 claims description 65
- 238000002360 preparation method Methods 0.000 claims description 55
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 48
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 45
- 229960002073 sertraline Drugs 0.000 claims description 44
- 238000006243 chemical reaction Methods 0.000 claims description 40
- 238000010438 heat treatment Methods 0.000 claims description 36
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 35
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 29
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 28
- 238000010992 reflux Methods 0.000 claims description 28
- 238000004090 dissolution Methods 0.000 claims description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 17
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 13
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 13
- 238000001816 cooling Methods 0.000 claims description 11
- 239000012453 solvate Substances 0.000 claims description 11
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 10
- 238000001556 precipitation Methods 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 208000019906 panic disease Diseases 0.000 claims description 8
- 239000012454 non-polar solvent Substances 0.000 claims description 7
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 6
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims description 6
- 230000001376 precipitating effect Effects 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 239000011877 solvent mixture Substances 0.000 claims description 3
- 150000004682 monohydrates Chemical group 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000003944 tolyl group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 48
- 239000002585 base Substances 0.000 description 46
- 239000013078 crystal Substances 0.000 description 31
- 238000001914 filtration Methods 0.000 description 26
- 239000000843 powder Substances 0.000 description 11
- 238000010908 decantation Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- 230000002335 preservative effect Effects 0.000 description 7
- 239000007858 starting material Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 4
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002083 X-ray spectrum Methods 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- -1 monosolvates Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- STMOVTSFWYRCOB-DKWTVANSSA-N (2s)-2-amino-3-hydroxypropanoic acid;hydrochloride Chemical compound Cl.OC[C@H](N)C(O)=O STMOVTSFWYRCOB-DKWTVANSSA-N 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- NSILVESQCSUIAJ-UHFFFAOYSA-M hexocyclium methyl sulfate Chemical class COS([O-])(=O)=O.C1C[N+](C)(C)CCN1CC(O)(C=1C=CC=CC=1)C1CCCCC1 NSILVESQCSUIAJ-UHFFFAOYSA-M 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- BLFQGGGGFNSJKA-XHXSRVRCSA-N sertraline hydrochloride Chemical compound Cl.C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 BLFQGGGGFNSJKA-XHXSRVRCSA-N 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical class CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Chemical class 0.000 description 1
- 0 Cc1ccc([C@]2c3ccccc3[C@@](*)CC2)cc1Cl Chemical compound Cc1ccc([C@]2c3ccccc3[C@@](*)CC2)cc1Cl 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Chemical class 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical class CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Chemical class 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Chemical class 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Chemical class 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Chemical class 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000441 X-ray spectroscopy Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000012615 aggregate Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Chemical class 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 229910000393 dicalcium diphosphate Inorganic materials 0.000 description 1
- AXDDJHKBOYNJPY-UHFFFAOYSA-L dipotassium;carboxylato carbonate Chemical compound [K+].[K+].[O-]C(=O)OC([O-])=O AXDDJHKBOYNJPY-UHFFFAOYSA-L 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Chemical class 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Chemical class 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Chemical class 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical class OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Chemical class 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 208000007656 osteochondritis dissecans Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000003303 reheating Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000002411 thermogravimetry Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 229940020965 zoloft Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
- C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17134199P | 1999-12-21 | 1999-12-21 | |
| US60/171,341 | 1999-12-21 | ||
| US18733600P | 2000-03-06 | 2000-03-06 | |
| US60/187,336 | 2000-03-06 | ||
| US18791000P | 2000-03-08 | 2000-03-08 | |
| US60/187,910 | 2000-03-08 | ||
| US19060300P | 2000-03-20 | 2000-03-20 | |
| US60/190,603 | 2000-03-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20020062356A KR20020062356A (ko) | 2002-07-25 |
| KR100791872B1 true KR100791872B1 (ko) | 2008-01-07 |
Family
ID=27496950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020027007897A KR100791872B1 (ko) | 1999-12-21 | 2000-12-21 | 신규 서트랄린 염산염 다형, 그것의 제조 방법, 그것을 함유하는 조성물, 및 그것을 사용하는 방법 |
Country Status (19)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5845313A (en) | 1995-07-31 | 1998-12-01 | Lexar | Direct logical block addressing flash memory mass storage architecture |
| US6978342B1 (en) | 1995-07-31 | 2005-12-20 | Lexar Media, Inc. | Moving sectors within a block of information in a flash memory mass storage architecture |
| US6500987B1 (en) * | 1998-11-27 | 2002-12-31 | Teva Pharmaceutical Industries Ltd. | Sertraline hydrochloride polymorphs |
| US6495721B1 (en) * | 1999-08-09 | 2002-12-17 | Teva Pharmaceutical Industries Ltd. | Sertraline hydrochloride Form II and methods for the preparation thereof |
| TWI260315B (en) | 1999-10-29 | 2006-08-21 | Ciba Sc Holding Ag | Polymorphic forms of sertraline hydrochloride |
| SK8872002A3 (en) | 1999-12-21 | 2002-12-03 | Teva Pharma | Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them |
| US6552227B2 (en) * | 2000-03-14 | 2003-04-22 | Teva Pharmaceutical Industries Ltd. | Process for preparing (+)-cis-sertraline |
| WO2002096860A1 (en) * | 2001-05-31 | 2002-12-05 | Orion Corporation Fermion | Process for preparing sertraline intermediates |
| WO2002096859A1 (en) | 2001-05-31 | 2002-12-05 | Orion Corporation Fermion | Process for preparing sertraline hydrochloride polymorphic form ii |
| GB0123421D0 (en) | 2001-09-28 | 2001-11-21 | Memquest Ltd | Power management system |
| US6897340B2 (en) | 2002-04-29 | 2005-05-24 | Teva Pharmaceutical Industries Ltd. | Processes for preparation of polymorphic form II of sertraline hydrochloride |
| US20040220153A1 (en) * | 2002-09-24 | 2004-11-04 | Jost-Price Edward Roydon | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| US20040131672A1 (en) * | 2003-01-07 | 2004-07-08 | Nilobon Podhipleux | Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties |
| JP2007502329A (ja) | 2003-05-23 | 2007-02-08 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | セルトラリン組成物 |
| CA2537804A1 (en) * | 2003-09-05 | 2005-03-17 | Teva Pharmaceutical Industries Ltd | A recycling process for preparing sertraline |
| ZA200603502B (en) * | 2003-11-04 | 2008-02-27 | Cipla Ltd | Process for the preparation of polymorphs of selective serotonin reuptake inhibitor |
| US7464306B1 (en) | 2004-08-27 | 2008-12-09 | Lexar Media, Inc. | Status of overall health of nonvolatile memory |
| US7345201B2 (en) * | 2005-02-23 | 2008-03-18 | Teva Pharmaceutical Industries, Ltd. | Processes for preparing sertraline |
| WO2006103506A1 (en) * | 2005-03-31 | 2006-10-05 | Ranbaxy Laboratories Limited | Sertraline-containing pharmaceutical compositions and a process for preparation thereof |
| GB0507090D0 (en) * | 2005-04-07 | 2005-05-11 | Sandoz Ag | Process for preparing polymorphic form ll of sertraline hydrochloride |
| US7518019B2 (en) * | 2006-06-01 | 2009-04-14 | Hetero Drugs Limited | Processes for preparing sertraline hydrochloride crystalline forms |
| US20060257475A1 (en) * | 2006-08-17 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Stable Sertraline Hydrochloride Formulation and Method |
| CA2594198A1 (en) * | 2007-07-20 | 2009-01-20 | Apotex Pharmachem Inc. | A novel process for the preparation of sertraline hydrochloride form ii |
| FR2928148B1 (fr) * | 2008-02-28 | 2013-01-18 | Sanofi Aventis | Procede de preparation de combretastatine |
| KR102495018B1 (ko) | 2013-11-15 | 2023-02-06 | 아케비아 테라퓨틱스 인코포레이티드 | ｛[5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐]아미노｝아세트산의 고체형, 이의 조성물 및 용도 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5248699A (en) | 1992-08-13 | 1993-09-28 | Pfizer Inc. | Sertraline polymorph |
| US5734083A (en) | 1996-05-17 | 1998-03-31 | Torcan Chemical Ltd. | Sertraline polymorph |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4536518A (en) | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
| US5082970A (en) | 1991-03-06 | 1992-01-21 | Pfizer Inc. | Process for recycling amine isomer |
| GB9114947D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline |
| JP2002506844A (ja) | 1998-03-18 | 2002-03-05 | チバ スペシャルティ ケミカルズ ホールディング インコーポレーテッド | シクロヘキシリデンアミンのｃｉｓ−選択的接触水素化方法 |
| JP2000026379A (ja) * | 1998-07-08 | 2000-01-25 | Sumika Fine Chemicals Co Ltd | 塩酸セルトラリンメタノール和物および塩酸セルトラリンエタノール和物、ならびにそれらの製法 |
| EP1133459B1 (en) * | 1998-11-27 | 2006-01-11 | Teva Pharmaceutical Industries Ltd. | Sertraline hydrochloride form v |
| US6500987B1 (en) | 1998-11-27 | 2002-12-31 | Teva Pharmaceutical Industries Ltd. | Sertraline hydrochloride polymorphs |
| US6495721B1 (en) | 1999-08-09 | 2002-12-17 | Teva Pharmaceutical Industries Ltd. | Sertraline hydrochloride Form II and methods for the preparation thereof |
| TWI260315B (en) * | 1999-10-29 | 2006-08-21 | Ciba Sc Holding Ag | Polymorphic forms of sertraline hydrochloride |
| SK8872002A3 (en) * | 1999-12-21 | 2002-12-03 | Teva Pharma | Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them |
| IN192343B (US06858652-20050222-C00002.png) | 2000-05-26 | 2004-04-10 | Ranbaxy Lab Ltd |
-
2000
- 2000-12-21 SK SK887-2002A patent/SK8872002A3/sk unknown
- 2000-12-21 HU HU0204010A patent/HUP0204010A3/hu unknown
- 2000-12-21 US US09/746,320 patent/US6452054B2/en not_active Expired - Lifetime
- 2000-12-21 ES ES00990336T patent/ES2281374T3/es not_active Expired - Lifetime
- 2000-12-21 WO PCT/US2000/035178 patent/WO2001045692A1/en active IP Right Grant
- 2000-12-21 AT AT00990336T patent/ATE354358T1/de not_active IP Right Cessation
- 2000-12-21 EP EP00990336A patent/EP1248605B1/en not_active Expired - Lifetime
- 2000-12-21 YU YU47902A patent/YU47902A/sh unknown
- 2000-12-21 DE DE60033566T patent/DE60033566T2/de not_active Expired - Fee Related
- 2000-12-21 KR KR1020027007897A patent/KR100791872B1/ko not_active IP Right Cessation
- 2000-12-21 IL IL15033200A patent/IL150332A0/xx unknown
- 2000-12-21 CN CN00819123A patent/CN1434708A/zh active Pending
- 2000-12-21 JP JP2001546631A patent/JP4057295B2/ja not_active Expired - Fee Related
- 2000-12-21 PL PL00356452A patent/PL356452A1/xx unknown
- 2000-12-21 PT PT00990336T patent/PT1248605E/pt unknown
- 2000-12-21 EP EP07001701A patent/EP1797875A3/en not_active Withdrawn
- 2000-12-21 DK DK00990336T patent/DK1248605T3/da active
- 2000-12-21 AU AU27376/01A patent/AU780771B2/en not_active Ceased
-
2002
- 2002-06-18 IS IS6425A patent/IS6425A/is unknown
- 2002-06-21 HR HR20020543A patent/HRP20020543A2/hr not_active Application Discontinuation
- 2002-09-13 US US10/243,293 patent/US6858652B2/en not_active Expired - Lifetime
-
2007
- 2007-06-20 JP JP2007163172A patent/JP2007308505A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5248699A (en) | 1992-08-13 | 1993-09-28 | Pfizer Inc. | Sertraline polymorph |
| US5734083A (en) | 1996-05-17 | 1998-03-31 | Torcan Chemical Ltd. | Sertraline polymorph |
Also Published As
| Publication number | Publication date |
|---|---|
| DE60033566D1 (de) | 2007-04-05 |
| EP1248605B1 (en) | 2007-02-21 |
| US20030023117A1 (en) | 2003-01-30 |
| EP1797875A3 (en) | 2007-08-29 |
| HRP20020543A2 (en) | 2005-04-30 |
| KR20020062356A (ko) | 2002-07-25 |
| US6858652B2 (en) | 2005-02-22 |
| AU780771B2 (en) | 2005-04-14 |
| IL150332A0 (en) | 2002-12-01 |
| EP1248605A2 (en) | 2002-10-16 |
| HUP0204010A2 (hu) | 2003-04-28 |
| ES2281374T3 (es) | 2007-10-01 |
| WO2001045692A9 (en) | 2002-07-04 |
| PT1248605E (pt) | 2007-03-30 |
| JP4057295B2 (ja) | 2008-03-05 |
| DE60033566T2 (de) | 2007-10-25 |
| US20010041815A1 (en) | 2001-11-15 |
| IS6425A (is) | 2002-06-18 |
| US6452054B2 (en) | 2002-09-17 |
| WO2001045692A1 (en) | 2001-06-28 |
| DK1248605T3 (da) | 2007-03-19 |
| JP2007308505A (ja) | 2007-11-29 |
| CN1434708A (zh) | 2003-08-06 |
| JP2003518056A (ja) | 2003-06-03 |
| EP1248605A4 (en) | 2004-11-24 |
| SK8872002A3 (en) | 2002-12-03 |
| EP1797875A2 (en) | 2007-06-20 |
| AU2737601A (en) | 2001-07-03 |
| HUP0204010A3 (en) | 2006-02-28 |
| ATE354358T1 (de) | 2007-03-15 |
| PL356452A1 (en) | 2004-06-28 |
| YU47902A (sh) | 2005-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100791872B1 (ko) | 신규 서트랄린 염산염 다형, 그것의 제조 방법, 그것을 함유하는 조성물, 및 그것을 사용하는 방법 | |
| US20210002227A1 (en) | Crystalline forms of pitavastatin calcium | |
| US20070238738A1 (en) | Crystalline ziprasidone HCI and processes for preparation thereof | |
| EP1463711A1 (en) | A novel polymorph of sertraline hydrochloride and composition containing thereof, novel methods for preparation of sertraline hydrochloride polymorphs and amorphous form | |
| CA2437402A1 (en) | New crystal forms of oxcarbazepine and processes for their preparation | |
| US20240010629A1 (en) | Solid state form of lemborexant | |
| US20070208072A1 (en) | Maleate salt of tegaserod and crystalline forms thereof | |
| EP1772144A2 (en) | Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them | |
| US10759798B2 (en) | ABT-199 addition salt and crystal form thereof, preparation method thereof, and pharmaceutical composition thereof | |
| ZA200204971B (en) | Sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them. | |
| WO2024062344A1 (en) | Solid state forms of mesdopetam and salts therof | |
| WO2007016209A2 (en) | Pure 1,2-benzisoxazole-3-methane-sulfonic acid sodium salt and purification process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| LAPS | Lapse due to unpaid annual fee |